Cargando…

Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy

Genetic engineering has resulted in more than 50 recombinant bispecific antibody formats over the past two decades. Bispecific scFv antibodies represent a successful and promising immunotherapy platform that retargets cytotoxic T cells to tumor cells, with one scFv directed to tumor-associated antig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Shu-juan, Wei, Jia, Su, Shu, Chen, Fang-jun, Qiu, Yu-dong, Liu, Bao-rui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688922/ https://www.ncbi.nlm.nih.gov/pubmed/29151956 http://dx.doi.org/10.7150/jca.19501

Ejemplares similares

Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applications
por: Compte, Marta, et al.
Publicado: (2014)

Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy
por: Blanco, Belén, et al.
Publicado: (2021)

Editorial: Bispecific Antibodies for T-Cell Based Immunotherapy
por: Santich, Brian H., et al.
Publicado: (2020)

Bispecific antibodies come to the aid of cancer immunotherapy
por: Amelio, Ivano, et al.
Publicado: (2021)

Characterization of light chain c-terminal extension sequence variant in one bispecific antibody
por: Lin, Jun, et al.
Publicado: (2022)

Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
por: Zhou, Yanchen, et al.
Publicado: (2022)

Construction and expression of D-dimer and GPIIb/IIIa single-chain bispecific antibody
por: DAN, ZHAOKUI, et al.
Publicado: (2013)

Bispecific Antibody Format and the Organization of Immunological Synapses in T Cell-Redirecting Strategies for Cancer Immunotherapy
por: Carrasco-Padilla, Carlos, et al.
Publicado: (2022)

Current landscape and future directions of bispecific antibodies in cancer immunotherapy
por: Wei, Jing, et al.
Publicado: (2022)

Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
por: You, Gihoon, et al.
Publicado: (2021)

Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody
por: Moon, Dain, et al.
Publicado: (2022)

Bispecific Antibody-Bound T Cells as a Novel Anticancer Immunotherapy
por: Cho, Jaewon, et al.
Publicado: (2022)

Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question
por: Ordóñez-Reyes, Camila, et al.
Publicado: (2022)

Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6
por: Stadler, Christiane R., et al.
Publicado: (2015)

Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
por: Del Bano, Joanie, et al.
Publicado: (2015)

Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell–Redirected Bispecific Antibodies
por: Lussana, Federico, et al.
Publicado: (2021)

Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy
por: Yang, Yan, et al.
Publicado: (2021)

Editorial on “Cell Therapy, Bispecific Antibodies and Other Immunotherapies against Cancer”
por: Golubovskaya, Vita
Publicado: (2023)

A NOVEL IMMUNOSTIMULATORY PD-L1/OX40 TETRAVALENT BISPECIFIC ANTIBODY FOR CANCER IMMUNOTHERAPY
por: Li, Baocun, et al.
Publicado: (2023)

Effects of different interchain linkers on biological activity of an anti-prostate cancer single-chain bispecific antibody
por: Hao, Chao-hui, et al.
Publicado: (2015)

Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow
por: Ahamadi-Fesharaki, Raoufeh, et al.
Publicado: (2019)

Targeting non-human coronaviruses to human cancer cells using a bispecific single-chain antibody
por: Würdinger, T, et al.
Publicado: (2005)

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
por: Li, Tianye, et al.
Publicado: (2023)

Targeting immunotherapy for bladder cancer by using anti-CD3 × CD155 bispecific antibody
por: Ma, Wanru, et al.
Publicado: (2019)

A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy
por: Satta, Alessandro, et al.
Publicado: (2019)

Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
por: Barilà, Gregorio, et al.
Publicado: (2021)

Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy
por: Farhangnia, Pooya, et al.
Publicado: (2023)

A neutralizing bispecific single-chain antibody against SARS-CoV-2 Omicron variant produced based on CR3022
por: Yu, Kaikai, et al.
Publicado: (2023)

Bispecific antibodies and their applications
por: Fan, Gaowei, et al.
Publicado: (2015)

The making of bispecific antibodies
por: Brinkmann, Ulrich, et al.
Publicado: (2017)

First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach
por: Schaller, Teilo H, et al.
Publicado: (2020)

Bispecific Antibodies Progression in Malignant Melanoma
por: Tang, Juan, et al.
Publicado: (2022)

Investigation of the effect of salt additives in Protein L affinity chromatography for the purification of tandem single-chain variable fragment bispecific antibodies
por: Chen, Serene W., et al.
Publicado: (2020)

Corrigendum: A neutralizing bispecific single-chain antibody against SARS-CoV-2 Omicron variant produced based on CR3022
por: Yu, Kaikai, et al.
Publicado: (2023)

In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy
por: Kruse, Robert L., et al.
Publicado: (2017)

Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy
por: Lin, Tsung-Yi, et al.
Publicado: (2021)

LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer
por: Qiao, Guilin, et al.
Publicado: (2022)

Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy
por: Shin, Ha Gyeong, et al.
Publicado: (2022)

Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies
por: Carrara, Stefania C., et al.
Publicado: (2022)

Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha.
por: Schmidt, M., et al.
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_2vle99t9vnfvus9vti1do6153d